Guided Therapeutics

Guided Therapeutics Interest Coverage

The Interest Coverage Ratio of Guided Therapeutics (GTHP) as of Oct 19, 2026 is -5.32. In the previous year, Interest Coverage Ratio was -12.95 — a change of -58.89% (higher).

Interest Coverage

-5.32

YoY

-58.89%

Last updated:

Interest Coverage Ratio of Guided Therapeutics is 2024 -5.32 . Interest Coverage Ratio of Guided Therapeutics was 2023 -12.95 . It decreases by -58.89% higher compared to the previous year.

The Guided Therapeutics Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-0.41 USD
Jan 1, 2018
-1.05 USD
Jan 1, 2019
-0.91 USD
Jan 1, 2020
-1.32 USD
Jan 1, 2021
-2.99 USD
Jan 1, 2022
-5.95 USD
Jan 1, 2023
-12.95 USD
Jan 1, 2024
-5.32 USD
The Guided Therapeutics Interest Coverage history
YEARInterest CoverageYoY
-5.32-58.89%
-12.95+117.54%
-5.95+99.06%
-2.99+127.37%
-1.32+44.55%
-0.91-13.61%
-1.05+156.10%
-0.41-97.63%
-17.36+109.03%
-8.31-12.71%
-9.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

Interest Coverage Ratio of Guided Therapeutics is -5.32 in 2024.

Interest Coverage Ratio of Guided Therapeutics changed from -12.95 to -5.32, representing a -58.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Guided Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Guided Therapeutics

All Key Metrics — Guided Therapeutics